Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 6 mg injection every 2 weeks
EFPE_SC_6MG_Q2W
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -0.04 (-9.47 to 9.54) | 0.22 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.19 (-13.27 to 2.36) | 0.38 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 10.41 (1.04 to 45.90) | 0.48 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.67 (0.88 to 29.64) | 0.41 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.23 (0.00 to 5.66) | 0.76 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.67 (0.50 to 5.89) | 0.54 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.95 (1.47 to 6.22) | 0.60 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.21 (0.77 to 7.16) | 0.71 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.30 (0.54 to 3.25) | 0.66 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.71 (0.52 to 5.70) | 0.56 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.29 (0.43 to 13.14) | 0.48 |